Abstract
The metabolism and disposition of (1R,5S)-2,3,4,5-tetrahydro-7-(trifluoromethyl)-1,5-methano-1H-3-benzazepine (1), an α4β2 nicotinic acetylcholine receptor partial agonist, was investigated in Sprague-Dawley rats and cynomolgus monkeys receiving (1R,5S)-2,3,4,5-tetrahydro-7-(trifluoromethyl)-1,5-methano-1H-4[14C]-3- benzazepine hydrochloride ([14C]1) orally. Although both species chiefly (≥62%) cleared 1 metabolically, species-specific dispositional profiles were observed for both 1 and total radioactivity. Radioactivity was excreted equally in the urine and feces of intact rats but largely (72%) in bile in bile duct-cannulated animals. In monkeys, radioactivity recoveries were 50-fold greater in urine than feces and minimal (<5%) in bile. Both species metabolized 1 similarly: four-electron oxidation to one of four amino acids or two lactams (minor) and glucuronide formation (major). In rats, the latter pathway predominantly formed an N-carbamoyl glucuronide (M6), exclusively present in bile (69% of dose), whereas in monkeys it afforded an N-O-glucuronide (M5), a minor biliary component (4%) but the major plasma (62%) and urinary (42%) entity. In rats, first-pass hepatic conversion of 1 to M6, which was confirmed in rat hepatocytes, and its biliary secretion resulted in the indirect enterohepatic cycling of 1 via M6 and manifested in double-humped plasma concentration-time curves and long t1/2 for both 1 and total radioactivity. In monkeys, in which only M5 was formed, double-humped plasma concentration-time curves were absent, and moderate t1/2 for both 1 and total radioactivity were observed. A seemingly subtle, yet critical, difference in the chemical structures of these two glucuronide metabolites considerably affected the overall disposition of 1 in rats versus monkeys.
Footnotes
-
Article, publication date, and citation information can be found at http://dmd.aspetjournals.org.
doi:10.1124/dmd.109.030171
-
↵
The online version of this article (available at http://dmd.aspetjournals.org) contains supplemental material.
-
- P450
- cytochrome P450
- 1
- (1R,5S)-2,3,4,5-tetrahydro-7-(trifluoromethyl)-1,5-methano-1H-3-benzazepine hydrochloride
- [14C]1
- (1R,5S)-2,3,4,5-tetrahydro-7-(trifluoromethyl)-1,5-methano-1H-4[14C]-3-benzazepine hydrochloride
- 2
- (1R,5S)-2,3,4,5-tetrahydro-7-(trifluoromethyl)-1,5-methano-4-oxo-1H-3-benzazepine
- 3
- (1R,5S)-2,3,4,5-tetrahydro-7-(trifluoromethyl)-1,5-methano-2-oxo-1H-3-benzazepine
- 4
- (1R,5S)-2,3,4,5-tetrahydro-7-(trifluoromethyl)-1,5-methano-1H-3-benzazepine-3-carboxaldehyde
- PGRD
- Pfizer Global Research and Development
- RLM
- rat liver microsome
- MLM
- monkey liver microsome
- HPLC
- high-performance liquid chromatography
- LSC
- liquid scintillation counting
- LC/MS/MS
- liquid chromatography/tandem mass spectrometry
- RCF
- relative centrifugal force
- MRM
- multiple-reaction monitoring
- AUC
- area under the concentration-time curve
- kel
- elimination rate constant
- LC/MS/NMR
- liquid chromatography/mass spectrometry/nuclear magnetic resonance
- CID
- collision-induced dissociation
- EHC
- enterohepatic cycling
- FMO
- FAD-containing monooxygenase.
- Received September 8, 2009.
- Accepted November 6, 2009.
- Copyright © 2010 by The American Society for Pharmacology and Experimental Therapeutics
DMD articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|